| Literature DB >> 27880984 |
Luciano J Costa1, Kami Maddocks2, Narendranath Epperla3, Nishitha M Reddy4, Reem Karmali5, Elvira Umyarova6, Veronika Bachanova7, Cristiana Costa8, Martha J Glenn9, Julio C Chavez10, Oscar Calzada11, Frederick Lansigan8, Hossain Nasheed12, Stefan K Barta12, Zheng Zhou13, Michael Jaglal10, Saurabh Chhabra6, Francisco Hernandez-Ilizaliturri14, Ana C Xavier15, Amitkumar Mehta1, Deniz Peker16, Andreas Forero-Torres1, Zeina Al-Mansour17, Andrew M Evens17, Jonathon B Cohen11, Christopher R Flowers11, Timothy S Fenske3, Mehdi Hamadani3.
Abstract
The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse < 6 months from end of therapy (early relapse; ER). Median age was 58 years and response to salvage was 41.7%. Two-year OS was 18.5% in PP, 30.6% in RD and 45.5% in ER. The presence of PP, intermediate-high/high NCCN-IPI at time of PTF or MYC translocation predicted 2-year OS of 13.6% constituting ultra-high risk (UHR) features. Among the 132 patients who underwent autologous hematopoietic cell transplantation, 2-year OS was 74.3%, 59.6% and 10.7% for patients with 0,1 and 2-3 UHR features respectively. Patients with PTF and UHR features should be prioritized for clinical trials with newer agents and innovative cellular therapy.Entities:
Mesh：
Year: 2017 PMID： 27880984 PMCID： PMC5549936 DOI： 10.1002/ajh.24615
Source DB: PubMed Journal: Am J Hematol ISSN： 0361-8609 Impact factor: 10.047